Arena and Vivus Take Divergent Paths To CRL Response

Lorqess and Qnexa both have received "complete responses" from FDA, but the drastically different contents of the letters have shaped divergent responses from the drugs' sponsors.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet